In this interview, at ESMO 2018, Dr Raffaele Califano talks to touchONCOLOGY about epidermal growth factor receptor (EGFR) expression in non-small cell lung cancer (NSCLC). He explains the importance of detecting EGFR activity prior to treatment in order to treat the patient effectively. Dr Califano also discusses the results from several recent trials including the phase III FLAURA trial in mechanisms of acquired resistance, a phase II study of nazartinib in patients with treatment-naive EGFR-mutant NSCLC, and the phase Ib study in teliso-V monotherapy and in combination with erlotinib. Finally, he looks to the future of mechanisms of resistance and how best to tackle them.
1. What incidence of patients with non-small cell lung cancer (NSCLC) express EGFR, and how do management strategies differ in these patients? (0:11)
2. What new data around EGFR-mutated NSCLC is being presented at this year's ESMO congress, and what are the implications for clinical practice? (0:52)
3. What are the next steps in this field of research? (5:56)
Speaker disclosures: Raffaele Califano has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.